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Abstract: The purpose of this study was to define parameters which could 
be predictive of hepatic artery thrombosis, which continues to be a major 
complicating factor in pediatric liver transplantation. The hepatic blood 
flow of 14 pediatric liver patients (15 grafts) who weighed less than 15 kg 
was measured electromagnetically during orthotopic liver transplantation. 
The results of blood flow determination and the clinical data in 7 patients 
(8 grafts) who developed hepatic artery thrombosis were compared with 
those of 7 control patients. All patients with a hepatic arterial flow of less 
than 60 ml/min developed hepatic artery thrombosis (4/8 vs. 0/7; p < 0.05), 
and the patients with hepatic artery thrombosis exhibited higher total 
hepatic and portal vein flow per 100 gram of liver tissue (262 vs. 136 mIl 
min; p < 0.00 I and 222 vs. 80 ml/min; p < 0.025, respectively) as well as 
longer cold preservation time (384 vs. 326 min; p < 0.025). The results of 
our study suggest that hepatic arterial flows of less than 60 ml/min are 
critical for the development of hepatic artery thrombosis, and that portal 
venous overflow and increased preservation times may contribute to the 
development of hepatic artery thrombosis. 
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Hepatic artery thrombosis (HAT) continues to be 
a life-threatening complication of orthotopic liver 
transplantation (OLTx), especially in small children 
(1-3). The incidence of this devastating compli-
cation among pediatric OLTx recipients in several 
series varies from 11.8 to 25% (1-3), and the mor-
tality has been as high as 50% (1). HAT also ac-
counts for one of the main causes of retransplan-
tation in children (2, 4). Although rejection, infec-
tion, and technical problems such as intimal flap 
have been implicated as the etiology of HAT (1-3), 
little is known about the pathogenesis of this entity, 
which may develop in an allograft even under ideal 
circumstances. 
The purpose of this study was to determine the 
significance of the hemodynamics of the liver allo-
grafts as a predictive parameter for the develop-
ment of HAT after OLTx in pediatric patients, 
and to correlate this with and to determine other 
clinically relevant factors. 
Supported by Research Grants from the Veterans Adminis-
tration and Project Grant No. AM 29961 from the National 
Institute of Health, Bethesda, Maryland. 
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Patients and methods 
Between July 1, 1987 and October 23, 1987, 39 
pediatric OLTx were performed in 31 patients at 
the Children's Hospital of Pittsburgh. Of these, 25 
allografts in 20 patients underwent electromagnetic 
flow measurement of the hepatic artery (HA) and 
the portal vein (PV) during OLTx. The selection of 
these patients was based primarily on the avail-
ability of sterile probes. Two of these grafts re-
quired allograft right lobectomy pretransplant for 
volume reduction. Among these 25 allografts, 8 
grafts in 7 patients developed HAT, including both 
grafts with the allograft right lobectomy, 
Recipients who weighed less than 15 kg were 
analyzed in this study, since the incidence of HAT 
following OLTx is much higher in small children 
than in adults or large children (1, 2), and since 
none of the allograft recipients who underwent 
blood flow analysis and who weighed over 15 kg 
developed HAT. Therefore, the clinical data and 
the results of flow measurements among the 7 pa-
tients (8 grafts) who developed HAT were com-
pared with those of 7 recipients (control group) 
who did not develop HAT following OLTx. Ten 
allografts were excluded from this analysis, due to 
recipient body weight over 15 kg in 7 (16 to 40 kg, 
mean 26 kg), immediately postoperatively primary 
graft non-function in 2 and thrombosis of the right 
HA due to technical reasons in 1, following vascu-
lar reconstruction of the traumatized and transect-
ed small right HA originating from the superior 
mesenteric artery for which reconstruction was per-
formed by end-to-end anastomosis between the 
transected right HA and the donor splenic artery. 
Among 8 grafts with HAT, no obvious technical 
failure, such as anastomotic failure due to intimal 
flap or kinking of the HA, could be identified. The 
diagnosis of HAT was made either on exploratory 
laparotomy, or by the absence of HA flow on 
arteriography or on two consecutive doppler ultra-
sonograms. For all patients studied in this series, 
the donor allografts were harvested by the rapid 
perfusion technique (5) and preserved in Euro-Col-
lins solution (4°C). Veno-venous bypass was not 
used in any of these patients. All patients were 
hemodynamically stable at the time of hepatic 
blood flow measurements. Immunosuppression 
consisted of Cyclosporine and corticosteroids, and 
episodes of severe allograft rejection were treated 
with Orthoclone OKT® 3 (Ortho Pharmaceutical 
Co., Raritan, NJ). Immediately postoperatively, all 
patients received low molecular weight dextran in-
travenously at 5 mljh for 4 days and heparin 50 
units/kg subcutaneously every 12 h. Also, aspirin 
20 to 40 mg/d p.o. or per nasogastric tube were 
administered. The above anticoagulation or anti-
platelet therapy was discontinued when the patient 
demonstrated clinical or laboratory evidence of 
coagulopathy, as manifested by intra abdominal 
bleeding requiring blood replacement or a pro-
thrombin time of over 20 seconds for more than 
12 h posttransplant. 
Blood flow measurement 
Blood flows in the HA and PV were measured with 
a square-wave electromagnetic flowmeter, Clini-
flow II®, Model FM70lD (Carolina Medical Elec-
tronics, Inc., King, North Carolina). Probes which 
fit the vessels snugly were selected for the measure-
ment. A zero flow reference was obtained by pla-
cing the probes and an isolated ground in a plastic 
beaker filled with normal saline. At the time of 
flow measurement, the heart rate, blood pressure, 
central venous pressure, urine output and the dose 
of vasopressors were recorded. Cardiac output was 
not measured. However, none of the 14 patients 
studied showed any evidence of cardiogenic shock 
or hypovolemia at the time of blood flow measure-
ment: All of them demonstrated stable systemic 
HA thrombosis after pediatric OLTx 
blood pressure without tachycardia for age, and 
maintained urine output over 0.8 mljkgjmin. None 
of them was on vasopressor support in excess of 
renal dose dopamine. 
Clinical parameters 
The pertinent clinical factors evaluated and com-
pared between the two groups of patients studied 
included the age, the underlying liver disease, the 
number of allografts transplanted, the body 
weight, the donor to recipient body weight ratio, 
the HA diameter, the presence of HA anomalies, 
the methods of HA reconstruction, the cold preser-
vation time, the intervals between PV and HA 
anastomosis, anticoagulation and the T -lympho-
cyte crossmatch. The donor-to-recipient body 
weight ratio in the 2 patients who underwent allo-
graft right lobectomy and who developed HAT was 
excluded from the comparison. 
Statistical analyses 
Mann-Whitney's U and Chi-square tests were used 
for the statistical evaluation in this study. 
Results 
Table 1 lists the pertinent clinical and hepatic blood 
flow data in 7 patients (8 grafts) with HAT. The 
age ranged from 10 to 36 months with a mean of 
18.8 months and 4 patients were male (57.1 %). 
The body weight varied from 6.3 to 13.5 kg with 
a mean of 9.5 kg. The underlying liver disease in 
all patients was congenital biliary atresia. Case 7 
had already undergone 2 OLTx and required the 
3rd OLTx for rejection, and the 4th OLTx for HAT 
presenting as a bile leak from choledochojejunosto-
my. Case 3 exhibited zero flow in the HA on flow 
measurement but, since the HA pulse was palpable, 
no further attempt was made to reconstruct the 
HA, and a diagnosis of HAT was made on the 4th 
postoperative d. 
The diagnosis of HAT was made between 2 and 
15 d postoperatively, with a mean of 6.4 d. The 
diagnosis was made by exploratory laparotomy in 
1, arteriogram in 4 and two consecutive doppler 
ultrasonograms in 3 cases. Of these 7 patients, 
5 required retransplantation (71.4%) due to liver 
failure from HAT, and Case 4 is awaiting retrans-
plantation at home. In Case 3, the HA was as-
sumed to have recanalized (1), since repeated dop-
pler ultrasonogram demonstrated patent HA and 
the liver function remains near normal. 
In Case 6, anticoagUlation was discontinued 12 
h postoperatively because of intraperitoneal bleed-
ing. Also, this patient developed acute cellular re-
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HA thrombosis after pediatric OLTx 
Table 3. Comparison of clinical data between patients with and without hepatic artery thrombosis 
Age (mo) 
Diagnosis 
No. of allografts (i/II/Ili/IV) 
Body weight (Kg) 
With HAT 
(n=8) 
18.8±4.3* 
CBA(W 
6/0/1/1 
9.5 ± 2.4 
0.81 ± 0.22 (W 
Patients 
Without HAT 
(n=7) 
24.4± 13.6 
CBA (7t 
3/3/1/0 
10.9± 2.2 
p Value 
Donor/recipient body weight ratio 
HA diameter (mm) 
Arterial anomalies 
HA anastomosis (donor-recipient) 
Cold ischemia time (min) 
4.5± 1.0 
right and left 
branch (2)+ 
CA-CA (2)+ 
Ao-CA (W 
CA-CHA (W 
CA-Ao (2)+ 
384± 77 
1.00± 0.12 
4.5±0.6 
right branch (W 
right, left and PSB (W 
CA-CA (3), CA-Ao (W 
PSB-CA (W 
326±47 
46±14 
4/7 
1/7 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
p< 0.025 
NS 
NS 
NS 
Interval between PV and HA anastomosis (min) 
Anticoagulation (full) 
T-Iymhocyte crossmatch (positiveltotal) 
64±30 
5/8 
2/6 
* mean ± S.D.; ( ) + = number of patients; HAT = hepatic artery thrombosis; CBA = congenital biliary atresia; PSB = pulmonary sequestration branch; HA Rec = 
hepatic artery reconstruction; CA = celiac axis; Ao = aorta; CHA = common hepatic artery; HA = hepatic artery; PV = portal vein. 
jection proven by percutaneous liver biopsy on the 
postoperative d 9, for which Orthoclone OKT® 3 
was administered. HAT in this patient was iden-
tified 6 d later. In the other 6 patients, no evidence 
of rejection was observed or documented post-
operatively. Of the 5 grafts with HAT which were 
replaced later (Case 1,2,5,6 and 7a), 1 (Case 7a) 
whose HAT was diagnosed on posttransplant d 4 
exhibited mild acute cellular rejection, which was 
considered to be due to reduction in immunosup-
pression for bile peritonitis from the disruption 
of the choledochojejunostomy secondary to HAT. 
Case 6, who was the only patient who demon-
strated clincial evidence of acute cellular rejection, 
showed no evidence of rejection in the replaced 
allograft. 
Cases 2 and 6 underwent allograft right lobec-
tomy for volume reduction at the back table prior 
to revascularization. 
Table 2 shows the pertinent clinical and hepatic 
blood flow data in 7 patients without HAT (con-
trol). Four patients are alive and well at home, 
whereas the other 3 patients died of infectious com-
plications. None of them demonstrated clinical or 
histological evidence of rejection. 
The clinical data for the patients with and with-
out HAT are compared in Table 3. The cold is-
chemia time of the allograft was longer in the pa-
tients with HAT (p < 0.025). Otherwise, no statisti-
cally significant difference could be identified in the 
age, the original diagnosis, the number of allografts 
transplanted, the recipient body weight, the donor-
to-recipient body weight ratio, the HA diameter, 
the presence ofHA anomalies, the interval between 
PV and HA anastomoses, postoperative anticoagu-
lation, and the T -lymphocyte crossmatch. Al-
though statistical significance was not achieved, 
HA anastomosis at the level of the recipient com-
mon HA with or without splenic artery ligation 
was performed in 3 out of 8 allografts with HAT, 
while all patients without HAT underwent either 
celiac axis to celiac axis anastomosis with splenic 
Table 4. Comparison of the results of blood flow determinations between patients with and without hepatic artery thrombosis 
HA flow (ml/min) 
HA flow (ml/min)/100 g liver 
PV flow (ml/min)/100 g liver 
HA/PV flow ratio 
Total hepatic flow (ml/min)/100 9 liver 
With HAT 
(n=8) 
103.8 ± 82.8' 
52.9±39.8 
Patients 
221.9 ± 128.8 (7) + 
0.37 ± 0.40 (W 
261.8± 127.9 (7)+ 
Without HAT 
(n=7) 
165.7 ± 121.1 
45.6 ± 30.0 
79.6 ± 15.0 (W 
0.79 ± 9.64 (W 
135.6± 16.6 (W 
, Mean ± S.D.; ( ) + = number of patients; HAT = hepatic artery thrombosis; HA = hepatic artery; PV = portal vein. 
p Value 
NS 
NS 
p<O.025 
NS 
p < 0.01 
187 
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artery ligation, or donor celiac axis to recIpIent 
aorta anastomosis with interposition of a donor 
iliac artery (6). 
Table 4 compares the blood flow data in patients 
with and without HAT. Although no statistically 
significant difference was seen in the HA flow per 
100 g of liver tissue, the PV flow per 100 g of liver 
tissue (p < 0.025) and the total hepatic blood flow 
per 100 g of liver tissue (p < 0.01) were both signifi-
cantly greater in those patients with HAT. The HA 
to PV flow ratio and the absolute HA flow tended 
to be lower in patients with HAT. All 4 grafts with 
an absolute HA flow of less than 60 mljmin at the 
time of flow measurement went on to develop HAT 
(4/8 vs. 0/7; p<0.05, X2 =4.77). 
Discussion 
The high incidence of HAT after OLTx among 
small pediatric patients in this series is consistent 
with previous reports (1-3). Klintmalm et al. (7) 
reported, in adult OLTx recipients, the results of 
blood flow measurements which showed no signifi-
cant correlation between the HA flow and the inci-
dence of HAT. However, our study among pedi-
atric OLTx patients weighing less than 15 kg dem-
onstrated a 100% incidence of HAT in allografts 
where the HA flow was less than 60 ml/min. Fur-
thermore, there was a significantly higher total 
hepatic as well as PV flow per 100 g of liver tissue 
in patients with HAT after OLTx. These par-
ameters were observed in the absence of any signifi-
cant difference in the clinical features other than 
the cold ischemia time between the two groups of 
patients. 
A reciprocal relationship in the blood flow be-
tween the HA and PV, in the innervated or denerva-
ted liver, is a known phenomenon (8, 9), and it is 
suggested that portal overflow may increase the 
vascular resistance to the HA, thereby predisposing 
the allograft to HAT. In our series, the donor to 
recipient body weight ratio tended to be lower 
among the patients with HAT, and the 2 allografts 
which underwent pre-transplant right lobectomy 
resulted in a small graft for recipient size, and both 
went on to develop HAT. This mismatch of the 
donor and recipient liver size, i.e, the placement of 
a small liver to a recipient with a larger native liver 
may be an important factor in the development of 
HAT in pediatric patients. 
The cold ischemia time was the only predictive 
clinical parameter for the development of HAT. 
This suggests that intimal damage or an increase 
in HA resistance from cellular swelling during cold 
storage (10, 11) is a factor for the development of 
HAT. Since the incidence of HAT seems to be lower 
with the use of University of Wisconsin (UW) solu-
188 
tion (12), a new preservation fluid which is effective 
in preventing cellular swelling (11), it is suggested 
that reduction of the arterial resistance of the graft 
may be a key factor in preventing HAT after pedi-
atric OLTx. 
In vascular surgery, the presence of a critical 
flow for the development of graft thrombosis, such 
as 100 ml/min for femoro-popliteal bypass (13) and 
50 ml/min for coronary artery bypass (14) has been 
reported. Although such a critical flow was not 
determined in adults by Klintmalm et al. (7), the 
fact that all 4 pediatric allografts with a HA flow 
of less than 60 ml/h developed HAT and that none 
of the other grafts studied developed HAT seems 
to indicate the presence of such a critically limiting 
flow in the allograft HA in children weighing less 
than 15 kg. 
Rejection has been known to predispose liver 
allografts to the development of HAT, by creating 
high resistance and low flow through the HA (1, 
2). In this study, it was only Case 6 of the HAT 
group (Table 1) in whom rejection in combination 
with the cessation of anticoagulation was thought 
to have precipitated the development of HAT. 
As to postoperative anticoagulation therapy, this 
study did not demonstrate any significant differ-
ence between the patients with and without HAT. 
Our recent investigation of pediatric OLTx with the 
use of multivariate analysis in 47 patients, however, 
identified that the postoperative anticoagulation 
treatment was the only independent variable as-
sociated with HAT (15). We therefore continue 
to use current anticoagulation regimen following 
pediatric OLTx. 
The electromagnetic flowmeter has been proven 
to be the most reliable method for direct measure-
ment of HA and PV blood flow (16). It is also safe, 
easy to apply and gives real-time flow readings. 
Our data suggest that in pediatric OLTx, especially 
in those who weigh less than 15 kg, blood flow 
measurements may be a useful predictor of HAT 
and may be considered an important adjunct in the 
overall technical management of these cases. 
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